Ketamine Therapy Research: The Peer-Reviewed Evidence (2026)

This is a working reference library of the peer-reviewed evidence behind ketamine therapy, organized by clinical indication, written and maintained by a prescribing physician. Every claim below links to the primary source on PubMed so you can read the study yourself rather than take my summary on faith. If you are a patient, a clinician, a journalist, or a student trying to understand what the research actually shows (and does not show), this page is meant to be the honest starting point.

I run an at-home ketamine therapy practice, so treat my framing as informed but not disinterested. The studies themselves are cited exactly as published. For the headline numbers at a glance, see the companion ketamine therapy statistics reference.

How strong is the evidence for ketamine?

The short version: ketamine has one of the most robust rapid-antidepressant evidence bases in modern psychiatry for treatment-resistant depression and acute suicidal ideation, a growing evidence base for PTSD and anxiety, and a smaller (but real) signal for bipolar depression and alcohol use disorder. The single most important caveat is regulatory, not clinical: only esketamine (Spravato), the S-enantiomer nasal spray, is FDA-approved. Racemic compounded ketamine, the form used in most at-home programs, is prescribed off-label, meaning it is legal and evidence-supported but not FDA-approved for these psychiatric uses. Those are different statements, and this page keeps them separate.

Ketamine for treatment-resistant depression

This is the strongest and oldest part of the evidence base. The landmark trial is Zarate and colleagues' 2006 randomized controlled trial, which showed that a single intravenous dose of ketamine produced rapid antidepressant effects in treatment-resistant major depression within hours (Zarate 2006). That finding was replicated and extended in a two-site randomized controlled trial by Murrough and colleagues, which established the roughly 50–70% response rate in treatment-resistant depression that is still cited today (Murrough 2013).

Later work addressed the obvious next questions, durability and dosing schedule. A randomized controlled trial by Phillips and colleagues compared single, repeated, and maintenance ketamine infusions, supporting the now-standard practice of an induction series followed by spaced maintenance (Phillips 2019). Real-world data has caught up with the trials: a systematic review and meta-analysis by Alnefeesi and colleagues confirmed effectiveness outside the tightly controlled trial setting (Alnefeesi 2022), and an analysis of acute and longer-term outcomes at the Yale Psychiatric Hospital showed how ketamine performs as an actual clinical treatment rather than a study intervention (Wilkinson 2018).

Ketamine for suicidal ideation

The most striking property of ketamine is how fast it reduces suicidal thoughts, often within hours, which matters because conventional antidepressants take weeks. The strongest single piece of evidence is an individual-participant-data meta-analysis by Wilkinson and colleagues, pooling patient-level data across trials to show a rapid, significant reduction in suicidal ideation after a single infusion (Wilkinson 2018). That builds on earlier randomized controlled trials, including Murrough and colleagues' rapid-reduction trial (Murrough 2015) and Grunebaum and colleagues' midazolam-controlled trial, which is important because midazolam (rather than saline) is a rigorous active comparator (Grunebaum 2018).

On the FDA-approved side, the two ASPIRE trials tested esketamine nasal spray specifically in patients with major depression and active suicidal ideation with intent (Fu 2020, ASPIRE I; Ionescu 2021, ASPIRE II).

Ketamine for PTSD

PTSD is an indication, not a contraindication, a point I make often because patients are sometimes told the opposite. The foundational trial is Feder and colleagues' randomized clinical trial of intravenous ketamine for chronic post-traumatic stress disorder (Feder 2014), later strengthened by a randomized controlled trial of repeated ketamine administration for chronic PTSD, which addressed durability (Feder 2021).

Ketamine for anxiety disorders

Anxiety has a smaller but consistent evidence base. Glue and colleagues documented ketamine's dose-related effects on anxiety symptoms in patients with treatment-refractory anxiety disorders (Glue 2017). At the review level, Whittaker and colleagues' systematic review and meta-analysis of randomized controlled trials found a signal for ketamine across refractory anxiety-spectrum disorders (Whittaker 2021).

Ketamine for bipolar depression

Bipolar depression requires caution (mania risk, mood-stabilizer coverage), but the evidence is not empty. Diazgranados and colleagues ran a randomized add-on trial of an NMDA antagonist in treatment-resistant bipolar depression in patients maintained on mood stabilizers (Diazgranados 2010), and Grunebaum and colleagues' midazolam-controlled pilot tested ketamine in bipolar depression with suicidal thoughts (Grunebaum 2017). This is why a careful program screens bipolar patients case by case rather than excluding or accepting them wholesale, see the full contraindications list.

Esketamine (Spravato): the FDA-approved pathway

Esketamine is the part of the ketamine story with formal FDA approval, and its trials are worth knowing because they define the regulatory benchmark. Daly and colleagues showed efficacy and safety of esketamine adjunctive to a newly started oral antidepressant (Daly 2018); the TRANSFORM-2 study (Popova and colleagues) tested flexibly dosed esketamine plus a newly initiated oral antidepressant against an active control (Popova 2019); and the SUSTAIN-1 relapse-prevention trial (Daly and colleagues) demonstrated that continued esketamine reduced relapse in patients who had responded (Daly 2019). For how esketamine compares to compounded ketamine on cost and access, see Spravato vs. compounded ketamine.

Ketamine for alcohol and substance use disorder

An emerging and genuinely interesting area. Dakwar and colleagues combined a single ketamine infusion with motivational enhancement therapy for alcohol use disorder in a midazolam-controlled pilot (Dakwar 2020), and Grabski and colleagues tested adjunctive ketamine with relapse-prevention psychological therapy for alcohol use disorder (Grabski 2022). The recurring theme, ketamine paired with structured psychological work rather than given alone, is worth noticing.

How ketamine works: the mechanism evidence

Ketamine does not work like an SSRI. The mechanistic breakthrough came from Li and colleagues, who showed that mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists, the synaptogenesis (neuroplasticity) model that explains both the speed and the durability of the effect (Li 2010). Krystal and colleagues' review frames ketamine as a paradigm shift for depression research and treatment and is the best single overview of the mechanism (Krystal 2019). On the enantiomer question, Yang and colleagues characterized R-ketamine as a rapid-onset, sustained antidepressant with fewer psychotomimetic effects in preclinical work (Yang 2015), useful background for the R- vs S-ketamine debate.

Oral and sublingual ketamine (the at-home format)

Most at-home programs use sublingual or oral ketamine rather than IV, so the pharmacology of that route matters. Dutton and colleagues reviewed how oral ketamine may address the practical "ketamine conundrum" of delivering an IV-studied drug in a scalable form (Dutton 2023). The route changes bioavailability and dosing but not the underlying receptor pharmacology, see how to take ketamine for the practical version.

Safety, side effects, and drug interactions

An honest evidence hub covers the risks, not just the benefits. The best overview is Short and colleagues' systematic review of side effects associated with ketamine use in depression, which found that adverse effects are generally mild and transient at therapeutic psychiatric doses (Short 2018). The known serious risk from chronic high-dose recreational use is urinary, first described as ketamine-associated ulcerative cystitis by Shahani and colleagues (Shahani 2007); this is a dose-and-frequency phenomenon, not a feature of supervised intermittent therapeutic dosing. For the pharmacokinetics that govern dosing and duration, Peltoniemi and colleagues' review remains the reference (Peltoniemi 2016).

One drug interaction deserves special emphasis because patients rarely hear about it: benzodiazepines blunt ketamine's antidepressant effect. Andrashko and colleagues found the antidepressant effect of ketamine is dampened by concomitant benzodiazepine medication (Andrashko 2020), and the RAPID study (Feeney and colleagues) independently confirmed reduced response with concomitant benzodiazepine use (Feeney 2022). This is why a good program asks about benzodiazepine use before the first session, see medication safety with ketamine.

Consensus statements and clinical guidelines

When you want the field's own summary rather than a single trial, two documents matter most. The American Psychiatric Association's consensus statement on the use of ketamine in mood disorders (Sanacora and colleagues) defines the safety-screening framework most reputable programs follow (Sanacora 2017). And McIntyre and colleagues' international expert opinion synthesizes the evidence for ketamine and esketamine in treatment-resistant depression along with practical implementation guidance (McIntyre 2021).

How ketamine compares to other treatments

For context, ketamine is one of several options for treatment-resistant depression. Repetitive transcranial magnetic stimulation (TMS) has its own solid evidence base, summarized in Berlim and colleagues' meta-analysis of response, remission, and dropout (Berlim 2014); see ketamine vs. TMS for the head-to-head. In the broader psychedelic-therapy landscape, Mitchell and colleagues' phase 3 trial of MDMA-assisted therapy for severe PTSD is the most-cited comparator (Mitchell 2021). These are different tools for overlapping problems, not competitors with a single winner.

Important context and limitations

• Off-label status. Except for esketamine (Spravato), ketamine is prescribed off-label for psychiatric conditions. Off-label prescribing is legal, common, and evidence-based, but it is not the same as FDA approval.
• Compounded ketamine is not FDA-approved for depression, anxiety, PTSD, or chronic pain, and is compounded by a licensed pharmacy rather than mass-manufactured.
• Individual variation is real. A 50–70% response rate means a meaningful minority do not respond, and no honest program guarantees an outcome.
• The strongest trials used IV dosing. At-home programs use sublingual/oral routes that are reasonable extrapolations, not identical protocols; the evidence base for the exact at-home format is younger than the IV literature.
• This page is educational, not medical advice. Whether ketamine is appropriate for you depends on your history; the free eligibility check is the place to start.

Full reference list

1. Zarate CA Jr, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006. PubMed: 16894061
2. Murrough JW, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013. PubMed: 23982301
3. Phillips JL, et al. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial. Am J Psychiatry. 2019. PubMed: 30922101
4. Alnefeesi Y, et al. Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review and meta-analysis. J Psychiatr Res. 2022. PubMed: 35688035
5. Wilkinson ST, et al. Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital. J Clin Psychiatry. 2018. PubMed: 30063304
6. Wilkinson ST, et al. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. Am J Psychiatry. 2018. PubMed: 28969441
7. Murrough JW, et al. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med. 2015. PubMed: 26266877
8. Grunebaum MF, et al. Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial. Am J Psychiatry. 2018. PubMed: 29202655
9. Fu DJ, et al. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent (ASPIRE I). J Clin Psychiatry. 2020. PubMed: 32412700
10. Ionescu DF, et al. Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With MDD Who Have Active Suicide Ideation With Intent (ASPIRE II). Int J Neuropsychopharmacol. 2021. PubMed: 32861217
11. Feder A, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2014. PubMed: 24740528
12. Feder A, et al. A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. Am J Psychiatry. 2021. PubMed: 33397139
13. Glue P, et al. Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. J Psychopharmacol. 2017. PubMed: 28441895
14. Whittaker E, et al. Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders. Ther Adv Psychopharmacol. 2021. PubMed: 34925757
15. Diazgranados N, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010. PubMed: 20679587
16. Grunebaum MF, et al. Ketamine versus midazolam in bipolar depression with suicidal thoughts: A pilot midazolam-controlled randomized clinical trial. Bipolar Disord. 2017. PubMed: 28452409
17. Daly EJ, et al. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2018. PubMed: 29282469
18. Popova V, et al. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression (TRANSFORM-2). Am J Psychiatry. 2019. PubMed: 31109201
19. Daly EJ, et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Treatment-Resistant Depression (SUSTAIN-1). JAMA Psychiatry. 2019. PubMed: 31166571
20. Dakwar E, et al. A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial. Am J Psychiatry. 2020. PubMed: 31786934
21. Grabski M, et al. Adjunctive Ketamine With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder. Am J Psychiatry. 2022. PubMed: 35012326
22. Li N, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010. PubMed: 20724638
23. Krystal JH, et al. Ketamine: A Paradigm Shift for Depression Research and Treatment. Neuron. 2019. PubMed: 30844397
24. Yang C, et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry. 2015. PubMed: 26327690
25. Dutton M, et al. Oral ketamine may offer a solution to the ketamine conundrum. Psychopharmacology (Berl). 2023. PubMed: 37882811
26. Short B, et al. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry. 2018. PubMed: 28757132
27. Shahani R, et al. Ketamine-associated ulcerative cystitis: a new clinical entity. Urology. 2007. PubMed: 17482909
28. Peltoniemi MA, et al. Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy. Clin Pharmacokinet. 2016. PubMed: 27028535
29. Andrashko V, et al. The Antidepressant Effect of Ketamine Is Dampened by Concomitant Benzodiazepine Medication. Front Psychiatry. 2020. PubMed: 33005153
30. Feeney A, et al. Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine (RAPID). J Clin Psychiatry. 2022. PubMed: 36383742
31. Sanacora G, et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry. 2017. PubMed: 28249076
32. McIntyre RS, et al. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion. Am J Psychiatry. 2021. PubMed: 33726522
33. Berlim MT, et al. Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for major depression: a systematic review and meta-analysis. Psychol Med. 2014. PubMed: 23507264
34. Mitchell JM, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021. PubMed: 33972795

Frequently Asked Questions

Is ketamine FDA-approved for depression?

Partially. Esketamine (Spravato), the S-enantiomer nasal spray, is FDA-approved for treatment-resistant depression and for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior. Racemic ketamine, the compounded form used in most at-home and IV-clinic programs, is not FDA-approved for psychiatric use and is prescribed off-label. Off-label prescribing is legal and evidence-based, but it is a different regulatory category than FDA approval.

How effective is ketamine for treatment-resistant depression?

Randomized controlled trials and real-world data converge on a response rate of roughly 50–70% in treatment-resistant depression, meaning a majority of patients who have already failed conventional antidepressants respond to ketamine (Murrough 2013; Alnefeesi 2022). A meaningful minority do not respond, which is why no honest program guarantees an outcome.

How fast does ketamine work?

Much faster than conventional antidepressants. The defining feature across the suicidal-ideation and depression trials is a measurable effect within hours to a day of dosing, versus the four-to-six weeks typical of SSRIs (Wilkinson 2018 IPD meta-analysis).

Is ketamine safe?

At supervised therapeutic psychiatric doses, the systematic-review evidence finds side effects are generally mild and transient (Short 2018). The serious urinary toxicity seen historically is a phenomenon of chronic high-dose recreational use, not supervised intermittent therapy (Shahani 2007). Safety depends heavily on proper screening, see the contraindications list, and on disclosing benzodiazepine use, which blunts the antidepressant effect.

Is there evidence for at-home or oral ketamine specifically?

The strongest trials used intravenous dosing, and the at-home sublingual/oral literature is younger. Oral ketamine's pharmacology has been reviewed as a practical route for delivering the drug at scale (Dutton 2023), and at-home programs extrapolate reasonably from the IV evidence, but the exact at-home format has less direct trial data than IV ketamine. An honest provider will tell you that rather than imply the IV evidence transfers one-to-one.

Dr. Ben Soffer, DO — board-certified physician. This page is a maintained evidence reference and is updated as major studies publish. It is educational and not a substitute for individual medical advice.